Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Plasma cell leukemia – review of 40 cases from India

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Geetha Narayanan

Citation

Annals of Oncology (2015) 26 (suppl_9): 85-92. 10.1093/annonc/mdv526

Authors

G. Narayanan, A. Surendran, S.G. Nair, L. V Soman, P. N Purushothaman

Author affiliations

  • Medical Oncology, Regional Cancer Centre Thiruvananthapuram/Trivandrum, 695011 - Thiruvananthapuram (Trivandrum)/IN
More

Resources

Aim/Background

To study the clinical presentation, treatment and survival of patients with plasma cell leukemia.

Methods

This is a retrospective analysis of case records of patients with plasma cell leukemia treated in the department of medical oncology at Regional Cancer Centre, Trivandrum, India, during the period 1999-2013.

Results

Forty patients with plasma cell leukemia was seen during the period 1999- 2013. There were 23 males and 17 females. The median age was 56 years. The main symptoms at presentation were pallor, fever, pain, recurrent infections. The median duration of symptom was 2 months. Twenty two patients had a Hemoglobin less than 8gm/dl, and 20 had a platelet count less than 50000/mm3. Serum creatinine was elevated in 20 cases and hypercalcemia was present in 8 cases. IgG was the commonst subtype of M protein. ß microglobuin was elevated in 13 patients. Only 30 patients received chemotherapy which consisted of thaldex in 9, VAD in 7, Bortezomib containing regimen in 5, vincristine, cyclophosphamide and steroid in 4 and high dose dexona in 3. One patient underwent high dose melphalan followed by autologous stem cell transplant. Six patients were alive at 2 years. Among the 5 patients who received bortezomib, 3 were alive at 2 years (60%).

Conclusions

Plasma cell leukemia is a disease of the male, with median age at onset of 56 years. The prognosis is very poor with 2 year overall survival of 15%. Bortezomib containing regimens are very effective in plasma cell leukemia with 60% alive at 2 years.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings